总生存期-话题@MedSci

#总生存期#

65篇内容 | 828人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2170714, encodeId=174f21e071429, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a> <a href='/topic/show?id=68a790e741e' target=_blank style='color:#2F92EE;'>#视网膜母细胞瘤#</a>, objectTitle=WJP：2790例中国儿童视网膜母细胞瘤的临床分析, objectType=article, longId=802137, objectId=68ab80213e11, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696892662635_4754896.jpeg, objectUrl=/article/show_article.do?id=68ab80213e11, replyNumber=0, likeNumber=3, createdTime=2023-11-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=null, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=68ab80213e11, moduleTitle=WJP：2790例中国儿童视网膜母细胞瘤的临床分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68ab80213e11)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1516051, encodeId=6ea215160510b, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Nature Medicine：黑猩猩腺病毒+自扩增mRNA癌症疫苗，在临床试验中延长晚期实体瘤患者总生存期, objectType=article, longId=736369, objectId=39abe36369ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39abe36369ff, replyNumber=0, likeNumber=19, createdTime=2022-08-21, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39abe36369ff, moduleTitle=Nature Medicine：黑猩猩腺病毒+自扩增mRNA癌症疫苗，在临床试验中延长晚期实体瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39abe36369ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516050, encodeId=24ca151605089, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Euro Radio：用于预测食管癌患者无病生存期和总生存期的MR放射组学模型, objectType=article, longId=736296, objectId=0f70e36296c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f70e36296c7, replyNumber=0, likeNumber=31, createdTime=2022-08-21, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f70e36296c7, moduleTitle=Euro Radio：用于预测食管癌患者无病生存期和总生存期的MR放射组学模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f70e36296c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516048, encodeId=117b151604897, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期, objectType=article, longId=728460, objectId=e715e2846054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e715e2846054, replyNumber=0, likeNumber=18, createdTime=2022-06-03, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e715e2846054, moduleTitle=2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e715e2846054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516049, encodeId=9324151604971, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析, objectType=article, longId=728378, objectId=9bf0e283789c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bf0e283789c, replyNumber=0, likeNumber=0, createdTime=2022-06-02, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bf0e283789c, moduleTitle=ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bf0e283789c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516047, encodeId=660c151604e51, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=22, createdTime=2022-04-12, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516046, encodeId=9c4f1516046f8, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, objectType=article, longId=295593, objectId=ab9629559335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab9629559335, replyNumber=0, likeNumber=22, createdTime=2022-02-15, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab9629559335, moduleTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9629559335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516045, encodeId=15891516045eb, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Front Onco：基于 MRI 的骨髓放射组学诺模图预测多发性骨髓瘤患者的总生存期, objectType=article, longId=293284, objectId=90c1293284c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90c1293284c1, replyNumber=0, likeNumber=34, createdTime=2022-01-03, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90c1293284c1, moduleTitle=Front Onco：基于 MRI 的骨髓放射组学诺模图预测多发性骨髓瘤患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90c1293284c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516044, encodeId=51b11516044b9, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Front Oncol：化疗对转移性前列腺癌患者的总生存期影响, objectType=article, longId=221253, objectId=76b2221253f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76b2221253f9, replyNumber=0, likeNumber=23, createdTime=2021-12-01, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76b2221253f9, moduleTitle=Front Oncol：化疗对转移性前列腺癌患者的总生存期影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76b2221253f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516043, encodeId=5889151604385, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=DCR：术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标, objectType=article, longId=217965, objectId=b8f721e965b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8f721e965b8, replyNumber=0, likeNumber=0, createdTime=2021-10-02, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8f721e965b8, moduleTitle=DCR：术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8f721e965b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516042, encodeId=feaf151604264, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期, objectType=article, longId=217618, objectId=b49321e61895, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b49321e61895, replyNumber=0, likeNumber=18, createdTime=2021-09-26, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b49321e61895, moduleTitle=NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b49321e61895)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516041, encodeId=c86415160411b, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, objectType=article, longId=217593, objectId=2b2621e5937a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2621e5937a, replyNumber=0, likeNumber=18, createdTime=2021-09-26, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2621e5937a, moduleTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2621e5937a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516040, encodeId=e8b9151604080, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, objectType=article, longId=217099, objectId=442f21e09939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442f21e09939, replyNumber=0, likeNumber=18, createdTime=2021-09-16, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442f21e09939, moduleTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442f21e09939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516039, encodeId=794b1516039e7, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=J Thromb Haemost：华法林与低分子肝素治疗癌症相关血栓形成的总生存期, objectType=article, longId=217004, objectId=4ec521e004be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ec521e004be, replyNumber=0, likeNumber=18, createdTime=2021-09-14, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ec521e004be, moduleTitle=J Thromb Haemost：华法林与低分子肝素治疗癌症相关血栓形成的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ec521e004be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516038, encodeId=ba6f1516038c4, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！, objectType=article, longId=215518, objectId=62cd2155186f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cd2155186f, replyNumber=0, likeNumber=19, createdTime=2021-08-11, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cd2155186f, moduleTitle=J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62cd2155186f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, objectType=article, longId=212622, objectId=2be02126223c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be02126223c, replyNumber=0, likeNumber=24, createdTime=2021-06-13, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be02126223c, moduleTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be02126223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516036, encodeId=fcbf15160366a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, objectType=article, longId=212408, objectId=4ea821240891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea821240891, replyNumber=0, likeNumber=20, createdTime=2021-06-08, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea821240891, moduleTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea821240891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516035, encodeId=05ea1516035a5, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, objectType=article, longId=208701, objectId=790a208e01b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=790a208e01b0, replyNumber=0, likeNumber=27, createdTime=2021-03-21, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=790a208e01b0, moduleTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=790a208e01b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516034, encodeId=5220151603449, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, objectType=article, longId=208095, objectId=2339208095d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2339208095d3, replyNumber=0, likeNumber=0, createdTime=2021-03-09, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2339208095d3, moduleTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2339208095d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516033, encodeId=ed901516033ac, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, objectType=article, longId=207681, objectId=b94020e681d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94020e681d7, replyNumber=0, likeNumber=20, createdTime=2021-02-28, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94020e681d7, moduleTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94020e681d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#总生存期# #视网膜母细胞瘤#

WJP：2790例中国儿童视网膜母细胞瘤的临床分析

2023-11-24发表于上海

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Nature Medicine：黑猩猩腺病毒+自扩增mRNA癌症疫苗，在临床试验中延长晚期实体瘤患者总生存期

2022-08-21

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Euro Radio：用于预测食管癌患者无病生存期和总生存期的MR放射组学模型

2022-08-21

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期

2022-06-03

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析

2022-06-02

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

2022-02-15

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Front Onco：基于 MRI 的骨髓放射组学诺模图预测多发性骨髓瘤患者的总生存期

2022-01-03

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Front Oncol：化疗对转移性前列腺癌患者的总生存期影响

2021-12-01

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

DCR：术前营养评分可以作为 II 至 III 期结直肠癌患者总生存期和术后并发症的预测指标

2021-10-02

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：Tebentafusp治疗可改善转移性葡萄膜黑色素瘤患者总生存期

2021-09-26

heli0118 (审核中...)